Psoriasis is an immune-mediated chronic inflammatory skin disease that affects 2% to 3% of the world’s population. It is widely assumed that immune cells and cytokines acting together play a crucial part in the pathophysiology of psoriasis by promoting the excessive proliferation of skin keratinocytes and inflammatory infiltration. Interleukins (ILs), as a critical component of cytokines, have been closely associated with the pathogenesis and progression of psoriasis. This review summarizes the current contribution of ILs to psoriasis and describes the role each IL performs in psoriasis. Furthermore, the paper presents the therapeutic effects and application prospects of biologics developed for ILs in clinical treatment and experiments. The study aims to further the research on ILs in the treatment of psoriasis.
ChiricozziARomanelliPVolpeEBorsellinoGRomanelliM. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018;19(1):179.
4.
MeeJBJohnsonCMMorarNBurslemFGrovesRW. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol. 2007;171(1):32-42.
5.
YanoSBannoTWalshRBlumenbergM. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol. 2008;214(1):1-13.
SunPVuRDraganMHaenselDGutierrezGNguyenQ, et al. OVOL1 regulates psoriasis-like skin inflammation and epidermal hyperplasia. J Invest Dermatol. 2021;141(6):1542-1552.
8.
YegorovSBabenkoDKozhakhmetovSAkhmaltdinovaLKadyrovaINurgozhinaA, et al. Psoriasis is associated with elevated Gut IL-1alpha and intestinal microbiome alterations. Front Immunol. 2020;11:571319.
9.
CaiYXueFQuanCQuMLiuNZhangY, et al. A critical role of the IL-1beta-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol. 2019;139(1):146-156.
10.
CaiYXueFFlemingCYangJDingCMaY, et al. Differential developmental requirement and peripheral regulation for dermal Vgamma4 and Vgamma6T17 cells in health and inflammation. Nat Commun. 2014;5:3986.
11.
NiuXLHuangYGaoYLSunYZHanYChenHD, et al. Interleukin-18 exacerbates skin inflammation and affects microabscesses and scale formation in a mouse model of imiquimod-induced psoriasis. Chin Med J (Engl). 2019;132(6):690-698.
12.
RasmyHMikhaelNIsmailS. Interleukin-18 expression and the response to treatment in patients with psoriasis. Arch Med Sci. 2011;7(4):713-719.
13.
TominagaKYoshimotoTTorigoeKKurimotoMMatsuiKHadaT, et al. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. Int Immunol. 2000;12(2):151-160.
14.
ShimouraNNagaiHFujiwaraSJimboHYoshimotoTNishigoriC. Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. Arch Dermatol Res. 2017;309(4):315-321.
15.
YawalkarNKarlenSHungerRBrandCUBraathenLR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111(6):1053-1057.
16.
WittmannMPurwarRHartmannCGutzmerRWerfelT. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. J Invest Dermatol. 2005;124(6):1225-1233.
17.
LalorSJDunganLSSuttonCEBasdeoSAFletcherJMMillsKH. Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol. 2011;186(10):5738-5748.
18.
PatrunoCNapolitanoMBalatoNAyalaFMegnaMPatriA, et al. Psoriasis and skin pain: instrumental and biological evaluations. Acta Derm Venereol. 2015;95(4):432-438.
19.
SuttleMMEnokssonMZoltowskaAChatterjeeMNilssonGHarvimaIT. Experimentally induced psoriatic lesions associate with rapid but transient decrease in interleukin-33 immunostaining in epidermis. Acta Derm Venereol. 2015;95(5):536-541.
20.
BalatoADi CaprioRCantaLMattiiMLemboSRaimondoA, et al. IL-33 is regulated by TNF-alpha in normal and psoriatic skin. Arch Dermatol Res. 2014;306(3):299-304.
21.
MeephansanJTsudaHKomineMTominagaSOhtsukiM. Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol. 2012;132(11):2593-2600.
22.
MeephansanJKomineMTsudaHKarakawaMTominagaSOhtsukiM. Expression of IL-33 in the epidermis: the mechanism of induction by IL-17. J Dermatol Sci. 2013;71(2):107-114.
23.
AthariSKPoirierEBitonJSemeranoLHerveRRaffaillacA, et al. Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33. Arthritis Res Ther. 2016;18(1):143.
24.
Talabot-AyerDMcKeeTGindrePBasSBaetenDLGabayC, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 2012;79(1):32-37.
25.
RaimondoALemboSDi CaprioRDonnarummaGMonfrecolaGBalatoN, et al. Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage. Eur J Immunol. 2017;47(6):1062-1074.
26.
KashiwakuraJYanagisawaMLeeHOkamuraYSasaki-SakamotoTSaitoS, et al. Interleukin-33 synergistically enhances immune complex-induced tumor necrosis factor alpha and interleukin-8 production in cultured human synovium-derived mast cells. Int Arch Allergy Immunol. 2013;161(Suppl. 2):32-36.
27.
ShenJShangQWongCKLiEKKunEWChengIT, et al. Carotid plaque and bone density and microarchitecture in psoriatic arthritis: the correlation with soluble ST2. Sci Rep. 2016;6:32116.
28.
FosterAMBaliwagJChenCSGuzmanAMStollSWGudjonssonJE, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 2014;192(12):6053-6061.
29.
ShaoSFangHDangEXueKZhangJLiB, et al. Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4/IL-36R crosstalk. Front Immunol. 2019;10:746.
30.
BridgewoodCFearnleyGWBerekmeriALawsPMacleodTPonnambalamS, et al. IL-36gamma is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis. Front Immunol. 2018;9:200.
31.
JohnstonAXingXWolterinkLBarnesDHYinZReingoldL, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109-120.
32.
MarrakchiSGuiguePRenshawBRPuelAPeiXYFraitagS, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620-628.
33.
BachelezHChoonSEMarrakchiSBurdenADTsaiTFMoritaA, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981-983.
34.
BoutetMANervianiALliso-RiberaGLucchesiDPredilettoEGhirardiGM, et al. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Rheumatology (Oxford). 2020;59(4):828-838.
35.
SehatMTalaeiRDadgostarENikoueinejadHAkbariH. Evaluating serum levels of IL-33, IL-36, IL-37 and gene expression of IL-37 in patients with psoriasis vulgaris. Iran J Allergy Asthma Immunol. 2018;17(2):179-187.
36.
RonholtKNielsenALJohansenCVestergaardCFauerbyeALopez-ValesR, et al. IL-37 expression is downregulated in lesional psoriasis skin. Immunohorizons. 2020;4(11):754-761.
37.
TengXHuZWeiXWangZGuanTLiuN, et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production. J Immunol. 2014;192(4):1815-1823.
38.
SmithritheeRNiyonsabaFKiatsurayanonCUshioHIkedaSOkumuraK, et al. Human beta-defensin-3 increases the expression of interleukin-37 through CCR6 in human keratinocytes. J Dermatol Sci. 2015;77(1):46-53.
39.
TangRYiJYangJChenYLuoWDongS, et al. Interleukin-37 inhibits osteoclastogenesis and alleviates inflammatory bone destruction. J Cell Physiol. 2019;234(5):7645-7658.
40.
BoutetMABartGPenhoatMAmiaudJBrulinBCharrierC, et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin Exp Immunol. 2016;184(2):159-173.
41.
MercurioLMorelliMScarponiCEisenmesserEZDotiNPagnanelliG, et al. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis. 2018;9(11):1104.
42.
MermoudLShutovaMDiaz-BarreiroATalabot-AyerDDrukalaJWolnickiM, et al. IL-38 orchestrates proliferation and differentiation in human keratinocytes. Exp Dermatol. 2022;31(11):1699-1711.
43.
HanYMoraJHuardAda SilvaPWiechmannSPutyrskiM, et al. IL-38 ameliorates skin inflammation and limits IL-17 production from γδ T cells. Cell Rep. 2019;27(3):835-846.e5.
44.
KhandpurSGuptaVDasDSharmaA. Is there a correlation of serum and tissue T helper-1 and -2 cytokine profiles with psoriasis activity and severity? A cross-sectional study. Indian J Dermatol Venereol Leprol. 2018;84(4):414-418.
45.
NakamuraMToyodaMMorohashiM. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors. Br J Dermatol. 2003;149(4):718-730.
46.
FerencziKBurackLPopeMKruegerJGAustinLM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun. 2000;14(1):63-78.
47.
FranchiCCainelliGFrigerioEGaruttiCAltomareGF. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol. 2004;17(3):401-406.
48.
ZhangXShiLSunTGuoKGengS. Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients. BMC Microbiol. 2021;21(1):78.
49.
HirotsuCRydlewskiMAraujoMSTufikSAndersenML. Sleep loss and cytokines levels in an experimental model of psoriasis. PLoS One. 2012;7(11):e51183.
50.
GhoreschiKThomasPBreitSDugasMMailhammerRvan EdenW, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003;9(1):40-46.
51.
CooneyLAToweryKEndresJFoxDA. Sensitivity and resistance to regulation by IL-4 during Th17 maturation. J Immunol. 2011;187(9):4440-4450.
52.
ElderJTSartorCIBomanDKBenrazaviSFisherGJPittelkowMR. Interleukin-6 in psoriasis: expression and mitogenicity studies. Arch Dermatol Res. 1992;284(6):324-332.
53.
FujishimaSWatanabeHKawaguchiMSuzukiTMatsukuraSHommaT, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res. 2010;302(7):499-505.
54.
BlauveltA. IL-6 differs from TNF-alpha: unpredicted clinical effects caused by IL-6 blockade in psoriasis. J Invest Dermatol. 2017;137(3):541-542.
55.
TanakaRIchimuraYKubotaNSaitoANakamuraYIshitsukaY, et al. Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Commun Biol. 2020;3(1):571.
56.
XuHLiuJNiuMSongSWeiLChenG, et al. Soluble IL-6R-mediated IL-6 trans-signaling activation contributes to the pathological development of psoriasis. J Mol Med (Berl). 2021;99(7):1009-1020.
57.
HolskenSKreftingFSchedlowskiMSondermannW. Common fundamentals of psoriasis and depression. Acta Derm Venereol. 2021;101(11):adv00609.
58.
GarshickMSBarrettTJWechterTAzarchiSScherJUNeimannA, et al. Inflammasome signaling and impaired vascular health in psoriasis. Arterioscler Thromb Vasc Biol. 2019;39(4):787-798.
59.
SobolevVVDenisovaEVChebyshevaSNGeppeNAKorsunskayaIM. IL-6 gene expression as a marker of pathological state in psoriasis and psoriatic arthritis. Bull Exp Biol Med. 2022;173(1):77-80.
60.
JiangWYChattedeeADRaychaudhuriSPRaychaudhuriSKFarberEM. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol. 2001;40(11):699-703.
61.
Misiak-GalazkaMZozulaJRudnickaL. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355-370.
62.
MiddeHSPriyadarssiniMRajappaMMunisamyMMohan RajPSSinghS, et al. Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis. Clin Exp Dermatol. 2021;46(1):50-57.
63.
Ruiz-RomeuEFerranMde Jesus-GilCGarciaPSagristaMCasanovaJM, et al. Microbe-dependent induction of IL-9 by CLA(+) T cells in psoriasis and relationship with IL-17A. J Invest Dermatol. 2018;138(3):580-587.
64.
GugginoGCicciaFDi LibertoDLo PizzoMRuscittiPCiprianiP, et al. Interleukin (IL)-9/IL-9R axis drives γδ T cells activation in psoriatic arthritis patients. Clin Exp Immunol. 2016;186(3):277-283.
65.
Kundu-RaychaudhuriSAbriaCRaychaudhuriSP. IL-9, a local growth factor for synovial T cells in inflammatory arthritis. Cytokine. 2016;79:45-51.
66.
CicciaFGugginoGFerranteARaimondoSBignoneRRodolicoV, et al. Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis Rheumatol. 2016;68(8):1922-1931.
67.
MizumakiKHoriiMKanoMKomuroAMatsushitaT. Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells. Sci Rep. 2021;11(1):2106.
68.
MavropoulosAVarnaAZafiriouELiaskosCAlexiouIRoussaki-SchulzeA, et al. IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells. Clin Immunol. 2017;184:33-41.
69.
JinSPKohSJYuDAKimMWYunHTLeeDH, et al. Imiquimod-applied Interleukin-10 deficient mice better reflects severe and persistent psoriasis with systemic inflammatory state. Exp Dermatol. 2018;27(1):43-49.
70.
NakaoMSugayaMFujitaHMiyagakiTMorimuraSShibataS, et al. TLR2 deficiency exacerbates imiquimod-induced psoriasis-like skin inflammation through decrease in regulatory T cells and impaired IL-10 production. Int J Mol Sci. 2020;21(22):8560.
71.
MavropoulosAZafiriouESimopoulouTBrotisAGLiaskosCRoussaki-SchulzeA, et al. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. Rheumatology (Oxford). 2019;58(12):2240-2250.
72.
AsadullahKSterryWStephanekKJasulaitisDLeupoldMAudringH, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest. 1998;101(4):783-794.
73.
FriedrichMDockeWDKleinAPhilippSVolkHDSterryW, et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest Dermatol. 2002;118(4):672-677.
74.
YilmazBCakmak GencGKarakas CelikSSolak TekinNCanMDursunA. Association between psoriasis disease and IFN-λ gene polymorphisms. Immunol Invest. 2022;51(6):1772-1784.
75.
YinXZhangSLiBZhangYZhangX. IL28RA inhibits human epidermal keratinocyte proliferation by inhibiting cell cycle progression. Mol Biol Rep. 2019;46(1):1189-1197.
76.
WitteEKokolakisGWitteKWarszawskaKFriedrichMChristouD, et al. Interleukin-29 induces epithelial production of CXCR3A ligands and T-cell infiltration. J Mol Med (Berl). 2016;94(4):391-400.
77.
WolkKWitteKWitteERafteryMKokolakisGPhilippS, et al. IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med. 2013;5(204):204ra129.
78.
WitteEKokolakisGWitteKPhilippSDoeckeWDBabelN, et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol. 2014;134(11):2757-2767.
79.
LiHHLinYCChenPJHsiaoCHLeeJYChenWC, et al. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol. 2005;153(3):591-595.
80.
XuXPrensEFlorenciaELeenenPBoonLAsmawidjajaP, et al. Interleukin-17A drives IL-19 and IL-24 expression in skin stromal cells regulating keratinocyte proliferation. Front Immunol. 2021;12:719562.
81.
KonradRJHiggsRERodgersGHMingWQianYWBiviN, et al. Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay. Sci Rep. 2019;9(1):5211.
82.
WeiCCChenWYWangYCChenPJLeeJYWongTW, et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol. 2005;117(1):65-72.
83.
WangFLeeELowesMAHaiderASFuentes-DuculanJAbelloMV, et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J Invest Dermatol. 2006;126(7):1590-1599.
84.
BechROtkjaerKBirkelundSVorup-JensenTAggerRJohansenC, et al. Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin. Exp Dermatol. 2014;23(5):349-352.
85.
StenderupKRosadaCWorsaaeADagnaes-HansenFSteinicheTHasselagerE, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol. 2009;160(2):284-296.
86.
GottliebABKruegerJGSandberg LundbladMGothbergMSkolnickBE. First-in-human, phase 1, randomized, dose-escalation trial with recombinant anti-IL-20 monoclonal antibody in patients with psoriasis. PLoS One. 2015;10(8):e0134703.
87.
LinYCuiJLiangP. [Knockdown of interleukin 20 receptor 2 (IL-20R2) inhibits the development of psoriasis induced by imiquimod in mice]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2019;35(4):327-332.
88.
ChanJRBlumenscheinWMurphyEDiveuCWiekowskiMAbbondanzoS, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577-2587.
89.
HaHLWangHClaudioETangWSiebenlistU. IL-20-receptor signaling delimits IL-17 production in psoriatic inflammation. J Invest Dermatol. 2020;140(1):143-151.e3.
90.
MurakamiMHagforsenEMorhennVIshida-YamamotoAIizukaH. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20(10):845-847.
91.
NikamoPCheukSLysellJEnerbackCBerghKXu LandenN, et al. Genetic variants of the IL22 promoter associate to onset of psoriasis before puberty and increased IL-22 production in T cells. J Invest Dermatol. 2014;134(6):1535-1541.
92.
LiangJChenPLiCLiDWangJXueR, et al. IL-22 down-regulates Cx43 expression and decreases gap junctional intercellular communication by activating the JNK pathway in psoriasis. J Invest Dermatol. 2019;139(2):400-411.
93.
EkmanAKBivik EdingCRundquistIEnerbackC. IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis. J Invest Dermatol. 2019;139(7):1564-1573.e8.
94.
WangBHanDLiFHouWWangLMengL, et al. Elevated IL-22 in psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL/Bax. Apoptosis. 2020;25(9-10):663-673.
95.
AbdallahFHenrietESuetAArarAClemenconRMalingeJM, et al. miR-21-3p/IL-22 axes are major drivers of psoriasis pathogenesis by modulating keratinocytes proliferation-survival balance and inflammatory response. Cells. 2021;10(10):2547.
96.
AbdallahFPichonC. Evidence on the direct correlation between miR-31 and IL-22 axis in IMQ-induced psoriasis. Exp Dermatol. 2019;28(11):1336-1340.
97.
LiuTFengXLiaoY. miR-617 promotes the growth of IL-22-stimulated keratinocytes through regulating FOXO4 expression. Biochem Genet. 2021;59(2):547-559.
98.
HeQLiuNHuFShiQPiXChenH, et al. Circ_0061012 contributes to IL-22-induced proliferation, migration and invasion in keratinocytes through miR-194-5p/GAB1 axis in psoriasis. Biosci Rep. 2021;41(1):BSR20203130.
99.
LuJXuXLiYYuNDingYShiY. CircRAB3B suppresses proliferation, motility, cell cycle progression and promotes the apoptosis of IL-22-induced keratinocytes depending on the regulation of miR-1228-3p/PTEN axis in psoriasis. Autoimmunity. 2021;54(5):303-312.
100.
SheflerIPasmanik-ChorMKidronDMekoriYAHershkoAY. T cell-derived microvesicles induce mast cell production of IL-24: relevance to inflammatory skin diseases. J Allergy Clin Immunol. 2014;133(1):217-224.e1-3.
101.
KoksSKingoKVabritKRatsepRKarelsonMSilmH, et al. Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun. 2005;6(5):407-415.
102.
KingoKMossnerRKoksSRatsepRKrugerUVasarE, et al. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156(4):646-652.
103.
ItohTHatanoRKomiyaEOtsukaHNaritaYAuneTM, et al. Biological effects of IL-26 on T cell-mediated skin inflammation, including psoriasis. J Invest Dermatol. 2019;139(4):878-889.
104.
HatanoRItohTOtsukaHOkamotoSKomiyaEIwataS, et al. Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis. MAbs. 2019;11(8):1428-1442.
105.
AmeglioFBonifatiCFazioMMussiATrentoECordial FeiP, et al. Interleukin-11 production is increased in organ cultures of lesional skin of patients with active plaque-type psoriasis as compared with nonlesional and normal skin. Similarity to interleukin-1 beta, interleukin-6 and interleukin-8. Arch Dermatol Res. 1997;289(7):399-403.
106.
ZhangKLiuRYinGLiXLiJZhangJ. Differential cytokine secretion of cultured bone marrow stromal cells from patients with psoriasis and healthy volunteers. Eur J Dermatol. 2010;20(1):49-53.
107.
LiuRWangYZhaoXYangYZhangK. Lymphocyte inhibition is compromised in mesenchymal stem cells from psoriatic skin. Eur J Dermatol. 2014;24(5):560-567.
108.
LiuRYangYYanXZhangK. Abnormalities in cytokine secretion from mesenchymal stem cells in psoriatic skin lesions. Eur J Dermatol. 2013;23(5):600-607.
109.
LiuRChangWLiJChengYDangEYangX, et al. Mesenchymal stem cells in psoriatic lesions affect the skin microenvironment through circular RNA. Exp Dermatol. 2019;28(3):292-299.
110.
LiangNChangWPengACaoYLiJWangY, et al. Dermal mesenchymal stem cells from psoriatic lesions stimulate HaCaT cell proliferation, differentiation, and migration via activating the PI3K/AKT signaling pathway. Dermatology. 2022;238(2):283-291.
111.
TrepicchioWLOzawaMWaltersIBKikuchiTGilleaudeauPBlissJL, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest. 1999;104(11):1527-1537.
112.
RobertiMLRicottiniLCapponiASclauzeroEVicentiPFiorentiniE, et al. Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris. J Biol Regul Homeost Agents. 2014;28(1):133-139.
113.
Wcislo-DziadeckaDLGrabarekBKruszniewska-RajsCGolaJMSimkaKMazurekU. Analysis of the clinical response and changes in the expression of TNF-alpha and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab. Adv Clin Exp Med. 2020;29(2):235-241.
114.
FiechterRHde JongHMvan MensLJJFluriIATasSWBaetenDLP, et al. IL-12p40/IL-23p40 blockade with ustekinumab decreases the synovial inflammatory infiltrate through modulation of multiple signaling pathways including MAPK-ERK and Wnt. Front Immunol. 2021;12:611656.
115.
ElnabawiYADeyAKGoyalAGroenendykJWChungJHBelurAD, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721-728.
116.
TorresTPuigLVenderRLyndeCPiasericoSCarrascosaJM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567-579.
117.
GossecLSiebertSBergmansPde VlamKGremeseEJoven-IbanezB, et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022;81(6):823-830.
118.
FeldmanSRZhangJMartinezDJLopez-GonzalezLHoit MarchlewiczEShradyG, et al. Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis. Dermatol Online J. 2021;27(9).
119.
XuPXieNYeC. [Inhibitory effect of bispecific antibody targeting IL-12 p40 and TNF-alpha simultaneously on psoriasis in mice]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33(7):890-895.
120.
ZwickyPIngelfingerFSilvadeMeloBMRuchtiFScharliSPuertasN, et al. IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation. Sci Immunol. 2021;6(64):eabg9012.
121.
KuligPMusiolSFreibergerSNSchreinerBGyulvesziGRussoG, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7:13466.
122.
ChenWGongYZhangXTongYWangXFeiC, et al. Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model. J Dermatol Sci. 2017;85(2):115-123.
123.
ShibataSTadaYAsanoYYanabaKSugayaMKadonoT, et al. IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions. J Invest Dermatol. 2013;133(2):479-488.
124.
LiuXHuZZhangJMaTWuWWeiX, et al. IL-30 ameliorates imiquimod and K14-VEGF induced psoriasis-like disease by inhibiting both innate and adaptive immunity disorders. Biochem Biophys Res Commun. 2021;579:97-104.
125.
OmarNSLongXXianJAfewerkyHKHussainSGPengX. Serum interleukin-30 level in patients with psoriasis and its correlation with psoriasis severity: a case-control study. J Int Med Res. 2021;49(4):3000605211004039.
126.
NewcombDCBoswellMGZhouWHuckabeeMMGoleniewskaKSevinCM, et al. Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production. J Allergy Clin Immunol. 2011;127(4):1006-1013.e1-4.
127.
HijnenDKnolEFGentYYGiovannoneBBeijnSJKupperTS, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. J Invest Dermatol. 2013;133(4):973-979.
128.
ManXYLiWChenJQZhouJLandeckLZhangKH, et al. Impaired nuclear translocation of glucocorticoid receptors: novel findings from psoriatic epidermal keratinocytes. Cell Mol Life Sci. 2013;70(12):2205-2220.
129.
MirzaFNWangARamachandranSMDamskyWCohenJM. Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report. Br J Dermatol. 2021;185(2):432-434.
130.
Ruiz-GonzalezVCancino-DiazJCRodriguez-MartinezSCancino-DiazME. Keratinocytes treated with peptidoglycan from Staphylococcus aureus produce vascular endothelial growth factor, and its expression is amplified by the subsequent production of interleukin-13. Int J Dermatol. 2009;48(8):846-854.
131.
BluettJBartonA. What have genome-wide studies told us about psoriatic arthritis?Curr Rheumatol Rep. 2012;14(4):364-368.
132.
OngPYHamidQATraversJBStricklandIAl KerithyMBoguniewiczM, et al. Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitis. J Immunol. 2002;168(1):505-510.
133.
VilladsenLSSchuurmanJBeurskensFDamTNDagnaes-HansenFSkovL, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest. 2003;112(10):1571-1580.
134.
PandeyRAl-NuaimiYMishraRKSpurgeonSKGoodfellowM. Role of subnetworks mediated by [Formula: see text], IL-23/IL-17 and IL-15 in a network involved in the pathogenesis of psoriasis. Sci Rep. 2021;11(1):2204.
135.
SmithRLEyreSWarrenRBYoungHSGriffithsCEWorthingtonJ. No association between polymorphisms in the interleukin-15 gene and early-onset psoriasis in a UK cohort suggests heterogeneity for this susceptibility locus identified in Chinese psoriasis patients. J Invest Dermatol. 2008;128(12):2904-2905.
136.
ZhangXSunSHwangIToughDFSprentJ. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 1998;8(5):591-599.
137.
de Jesus-GilCRuiz-RomeuEFerranMSagristaMChiriacAGarciaP, et al. IL-15 and IL-23 synergize to trigger Th17 response by CLA(+) T cells in psoriasis. Exp Dermatol. 2020;29(7):630-638.
138.
CheukSSchlumsHGallais SerezalIMartiniEChiangSCMarquardtN, et al. CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin. Immunity. 2017;46(2):287-300.
139.
Purzycka-BohdanDSzczerkowska-DoboszAZablotnaMWierzbickaJPiotrowskaAZmijewskiMA, et al. Assessment of interleukin 16 serum levels and skin expression in psoriasis patients in correlation with clinical severity of the disease. PLoS One. 2016;11(10):e0165577.
140.
WagnerCLVisvanathanSElashoffMMcInnesIBMeasePJKruegerGG, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013;72(1):83-88.
141.
SarraMCarusoRCupiMLMonteleoneIStolfiCCampioneE, et al. IL-21 promotes skin recruitment of CD4(+) cells and drives IFN-γ-dependent epidermal hyperplasia. J Immunol. 2011;186(9):5435-5442.
142.
ShiYChenZZhaoZYuYFanHXuX, et al. IL-21 induces an imbalance of Th17/Treg cells in moderate-to-severe plaque psoriasis patients. Front Immunol. 2019;10:1865.
143.
KimHJKimSHKimTGParkJYLeeMKimDS, et al. Interleukin-21 receptor signalling is not critically required for imiquimod-induced psoriasiform dermatitis in mice. Exp Dermatol. 2018;27(2):191-195.
144.
ChenCTanLZhuWLeiLKuangYLiuP, et al. Targeting myeloid-derived suppressor cells is a novel strategy for anti-psoriasis therapy. Mediators Inflamm. 2020;2020:8567320.
145.
GedebjergAJohansenCKragballeKIversenL. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta Derm Venereol. 2013;93(2):150-155.
146.
El-BoghdadyNAIsmailMFAbd-AlhameedMFAhmedASAhmedHH. Bidirectional association between psoriasis and obesity: benefits and risks. J Interferon Cytokine Res. 2018;38(1):12-19.
147.
NiuJSongZYangXZhaiZZhongHHaoF. Increased circulating follicular helper T cells and activated B cells correlate with disease severity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;29(9):1791-1796.
148.
WangYWangLShiYWangFYangHHanS, et al. Altered circulating T follicular helper cell subsets in patients with psoriasis vulgaris. Immunol Lett. 2017;181:101-108.
149.
NumasakiMTsukamotoHTomiokaYNishiokaYOhruiT. A heterodimeric cytokine, consisting of IL-17A and IL-17F, promotes migration and capillary-like tube formation of human vascular endothelial cells. Tohoku J Exp Med. 2016;240(1):47-56.
150.
van der FitsLMouritsSVoermanJSKantMBoonLLamanJD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836-5845.
151.
LiYGoldenJBCamhiMIZhangXFritzYDiaconuD, et al. Protection from psoriasis-related thrombosis after inhibition of IL-23 or IL-17A. J Invest Dermatol. 2018;138(2):310-315.
152.
YoshikiRKabashimaKHondaTNakamizoSSawadaYSugitaK, et al. IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells. J Invest Dermatol. 2014;134(7):1912-1921.
153.
ParkYJKimYHLeeESKimYC. Comparative analysis of single-cell transcriptome data reveals a novel role of keratinocyte-derived IL-23 in psoriasis. Front Immunol. 2022;13:905239.
154.
Diaz-PerezJAKilleenMEYangYCareyCDFaloLDJrMathersAR. Extracellular ATP and IL-23 form a local inflammatory circuit leading to the development of a neutrophil-dependent psoriasiform dermatitis. J Invest Dermatol. 2018;138(12):2595-2605.
DapavoPSiliquiniNMastorinoLAvalloneGMerliMAgostiniA, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat. 2022;33(4):2352-2357.
157.
TorresTPuigLVenderRYeungJCarrascosaJMPiasericoS, et al. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891-904.
158.
HuangYHChangLCChangYCChungWHYangSFSuSC. Compositional alteration of gut microbiota in psoriasis treated with IL-23 and IL-17 inhibitors. Int J Mol Sci. 2023;24(5):4568.
159.
PensoLBergqvistCMeyerAHerlemontPWeillAZureikM, et al. Risk of Inflammatory bowel disease in patients with psoriasis and psoriatic arthritis/ankylosing spondylitis initiating interleukin-17 inhibitors: a nationwide population-based study using the French national health data system. Arthritis Rheumatol. 2022;74(2):244-252.
160.
YehNLHsuCYTsaiTFChiuHY. Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment. Clin Drug Investig. 2019;39(12):1195-1203.
161.
DuXYanCKongSCheDPengBZhuL, et al. Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes. Front Microbiol. 2023;14:1227309.
162.
FangHHouYZhuangHWangC. The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in psoriasis. New Microbiol. 2022;45(2):130-137.
163.
BrunoMDavidsonLKoenenHvan den ReekJvan CranenbroekBde JongE, et al. Immunological effects of anti‒IL-17/12/23 therapy in patients with psoriasis complicated by candida infections. J Invest Dermatol. 2022;142(11):2929-2939.e8.
